Number of shares and votes in Calliditas Therapeutics

Rhea-AI Summary

Calliditas Therapeutics AB (publ) has reported changes in its share structure due to the exercise of warrants under its long-term incentive programs. As of July 31, 2024, the company's total outstanding shares have increased to 59,941,465 ordinary shares, with an equal number of votes. The share capital has risen by SEK 14,455.12, from SEK 2,383,203.48 to SEK 2,397,658.60. These changes result from the exercise of warrants under the ESOP 2020 and LTIP 2021 programs. This information is disclosed in compliance with the Swedish Financial Instruments Trading Act.

Positive

• Increase in total outstanding shares indicates potential capital inflow
• Exercise of warrants suggests confidence in company's future prospects

Negative

• None.

STOCKHOLM, July 31, 2024 /PRNewswire/ -- During July, the number of shares and votes in Calliditas Therapeutics AB (publ) has changed due to the exercise of warrants under the company's long-term incentive program issued in 2020, ESOP 2020 and Board of Directors program LTIP 2021. As of today, the total number of outstanding shares in Calliditas Therapeutics AB (publ) amounts to 59,941,465 ordinary shares. The number of votes in Calliditas Therapeutics AB (publ) as of today amounts to 59,941,465. The share capital has increased by SEK 14,455.12 from SEK 2,383,203.48 to SEK 2,397,658.60.

For further information, please contact:

Åsa Hillsten, Head of IR & Sustainability, Calliditas

Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com

The information in the press release is such that Calliditas Therapeutics AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2 p.m. CEST on July 31, 2024.

About Calliditas

Calliditas Therapeutics is a commercial stage biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/calliditas-therapeutics/r/number-of-shares-and-votes-in-calliditas-therapeutics,c4018656

The following files are available for download:

https://mb.cision.com/Main/16574/4018656/2926878.pdf

Number of shares and votes July 2024 (Eng)

View original content:https://www.prnewswire.com/news-releases/number-of-shares-and-votes-in-calliditas-therapeutics-302211062.html

SOURCE Calliditas Therapeutics

FAQ

How many outstanding shares does Calliditas Therapeutics (CALT) have as of July 31, 2024?

As of July 31, 2024, Calliditas Therapeutics (CALT) has 59,941,465 outstanding ordinary shares.

What caused the change in Calliditas Therapeutics' (CALT) share count in July 2024?

The change in Calliditas Therapeutics' (CALT) share count was due to the exercise of warrants under the company's long-term incentive programs ESOP 2020 and LTIP 2021.

How much did Calliditas Therapeutics' (CALT) share capital increase in July 2024?

Calliditas Therapeutics' (CALT) share capital increased by SEK 14,455.12, from SEK 2,383,203.48 to SEK 2,397,658.60.

What is the total number of votes in Calliditas Therapeutics (CALT) as of July 31, 2024?

The total number of votes in Calliditas Therapeutics (CALT) as of July 31, 2024, is 59,941,465, equal to the number of outstanding shares.